@article {8022,
	title = {Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: A study by the Hellenic Cooperative Oncology Group},
	journal = {Journal of Clinical Oncology},
	volume = {22},
	year = {2004},
	note = {Cited By :61Export Date: 21 February 2017},
	month = {2004},
	pages = {2150 - 2154},
	abstract = {Purpose: Radical surgery represents the treatment of choice for carcinoma of the upper urinary tract. Nevertheless, approximately 50\% of patients with stage T >= 3 or lymph node involvement die from their disease, mainly as a result of the development of distant metastases. Therefore, there is a need for effective adjuvant systemic treatment. We prospectively studied a cohort of patients who underwent surgery for high-risk carcinoma of the upper urinary tract to assess the feasibility of the combination of paclitaxel and carboplatin as adjuvant treatment. Patients and Methods: Thirty-six patients with tumor stage >= 3 or lymph node involvement were treated with four cycles of paclitaxel at 175 mg/m2 and carboplatin (area under the curve 5, Calvert Formula) every 3 weeks following surgery. Results: Median follow-up was 40.6 months. Chemotherapy was well tolerated with 32 patients (89\%) receiving full carboplatin and paclitaxel doses without delays. The most frequent grade 3/4 toxicity was neutropenia (39\%), which was complicated with fever in only one case (3\%). Nonhematologic grade 3 or 4 toxicities were reported in only one case. Five-year survival was 52\% (95\% CI, 35\% to 69\%), while 5-year disease-free survival was 40.2\% (95\% CI, 15.8\% to 64.6\%). Local failure rate was 30\%, as opposed to 17\% of patients who developed distant metastases. No patients with grade 2 tumors relapsed during follow-up, as opposed to 60\% of patients with grade 3 tumors. Conclusion: Adjuvant chemotherapy with paclitaxel and carboplatin is feasible and may reduce the risk of distant metastases in high-risk upper urinary tract carcinoma. {\textcopyright} 2004 by American Society of Clinical Oncology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-2942696475\&doi=10.1200\%2fJCO.2004.09.043\&partnerID=40\&md5=d26b8994c6d4bb39a362eb48a51634fa},
	author = {Bamias, A. and Deliveliotis, C. and Fountzilas, G. and Gika, D. and Anagnostopoulos, A. and Zorzou, M.P. and Kastritis, E. and Constantinides, C. and Kosmidis, P. and Dimopoulos, M.A.}
}
